Haemonetics Corp
NYSE:HAE

Watchlist Manager
Haemonetics Corp Logo
Haemonetics Corp
NYSE:HAE
Watchlist
Price: 85.55 USD 0.14% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Haemonetics Corp?
Write Note

Haemonetics Corp
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Haemonetics Corp
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Haemonetics Corp
NYSE:HAE
Total Equity
$878.9m
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
1%
DENTSPLY SIRONA Inc
NASDAQ:XRAY
Total Equity
$2.5B
CAGR 3-Years
-21%
CAGR 5-Years
-13%
CAGR 10-Years
0%
ICU Medical Inc
NASDAQ:ICUI
Total Equity
$2B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
15%
Align Technology Inc
NASDAQ:ALGN
Total Equity
$3.9B
CAGR 3-Years
4%
CAGR 5-Years
25%
CAGR 10-Years
18%
Lantheus Holdings Inc
NASDAQ:LNTH
Total Equity
$1.2B
CAGR 3-Years
33%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Total Equity
$1.3B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
12%
No Stocks Found

Haemonetics Corp
Glance View

Market Cap
4.3B USD
Industry
Health Care

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 2,708 full-time employees. The firm provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

HAE Intrinsic Value
99.89 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Haemonetics Corp's Total Equity?
Total Equity
878.9m USD

Based on the financial report for Sep 28, 2024, Haemonetics Corp's Total Equity amounts to 878.9m USD.

What is Haemonetics Corp's Total Equity growth rate?
Total Equity CAGR 10Y
1%

Over the last year, the Total Equity growth was -2%. The average annual Total Equity growth rates for Haemonetics Corp have been 8% over the past three years , 9% over the past five years , and 1% over the past ten years .

Back to Top